Oral Abstract Session 01 - Global HIV Vaccine Enterprise

Recommendations

Info

POSTERS Posters Topic 11: T Cell Immunity P11.43 LB The Early Th17/Treg Ratio Predicts The Immune Activation Set Point In Patients With Primary HIV Infection M.F. Chevalier 1 , G. Petitjean 2 , C. Didier 2 , P. Girard 3 , L. Meyer 4 , F. Barré-Sinoussi 2 , D. Scott-Algara 2 , L. Weiss 5 1 Institut Pasteur; Université Paris Diderot, Paris, France; 2 Institut Pasteur, Paris, France; 3 AP-HP Hôpital Saint-Antoine, Paris, France; 4 INSERM U1018, Paris, France; 5 Université Paris Descartes; AP-HP; Institut Pasteur, Paris, France Background: Persistent systemic immune activation plays a central role in the pathogenesis of HIV disease. Impairment of the intestinal barrier and subsequent microbial translocation might be involved in chronic immune activation. Th17 cells are important in the maintenance of intact epithelium and host defense against extracellular pathogens. The ratio between the two closely related CD4 subsets Th17 and Tregs has been recently found to shrink with HIV/SIV disease progression. The aim of the study was to analyze, in patients with early primary HIV infection (PHI), the relationship between Th17/Treg ratio and the immune activation set point, known to predict disease progression. Methods: 27 patients with early PHI were included in a prospective longitudinal study and followed-up for 6 months. T-cell activation and CD4 + CD25 + CD127lowFoxp3 + Treg frequency were assessed on fresh PBMC. Th17 cells were quantified by intracellular cytokine staining on sorted peripheral CD4 T cells stimulated with PMA/ionomycin for 5h. Correlations were assessed using spearman non-parametric tests. Plasma I-FABP, a marker of mucosal damages and soluble CD14 (sCD14) were measured by ELISA. Results: A strong negative relationship was found at baseline between the Th17/Treg ratio and the proportion of activated CD8 T cells expressing CD38/HLA-DR (p=0.008) or Ki-67 (P=0.001). At baseline, Th17/Treg ratios also negatively correlated with sCD14 plasma levels (p=0.003). I-FABP levels, which were similar to controls at baseline, increased at month 6. The Th17/Treg ratio at baseline (but not the proportion of Th17 cells) negatively correlated with the frequency of HLA-DR + CD38 + or Ki-67 + CD8 T cells at month 6, defining the immune activation set point (p=0.02 and p=0.0005 respectively). sCD14 plasma levels were also found to predict the immune set point (p=0.02). Conclusion: Our data do not support early mucosal damages in PHI. However, the early Th17/Treg balance correlates with sCD14 levels and predicts the immune activation set point. 238 AIDS Vaccine 2012 P11.44 LB Comparable Antiviral Capacity but Favorable In Vitro Survival of CD8s from Elite Controllers Compared to Untreated Progressors D. Shasha 1 , F. Porichis 1 , K. Daniel 1 , O. Angiuli 1 , D.E. Kaufmann 1 , B. Walker1 1 1The Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA Background: CD8s inhibition of viral replication in vitro was demonstrated as one of the best laboratory correlates to HIV control. However, past studies invariably used CD8s which were rested in vitro for few days before antiviral capacity examined. This might suggest that the difference between CD8s from elite controllers (EC) and chronic progressors (CP) is not in their inhibition capacity but in their ability to retain cytotoxicity during prolonged incubation. Here we compared cytotoxicity and apoptosis of CD8s immediately after their purification (“fresh CD8s”) or 3 days after in vitro rest (“old CD8s”) Methods: Samples from 10 EC, 10 CP, 5 HAART treated and 5 HIV negative patients were examined. “Fresh” and “old” CD8s were used as effectors in viral inhibition assays. HIV-specific CD8s were quantified using tetramer staining. Annexin V binding was used to evaluate apoptosis. Results: Using “old” CD8s inhibition capacity was higher among EC compared to CP (logP24 reduction 1.225 vs 0.238, p=0.044). For both EC and CP inhibition was much stronger using “fresh” CD8s, but no significant difference was found between EC and CP (logP24 reduction: 3.13 vs 3.85, p=0.29). HIV negative subjects showed no inhibition using “fresh” or “old” CD8s. IL-2 partially rescued antiviral capacity of rested CD8s. Loss of HIV-specific CD8s measured by tetramer staining was higher in CP compared to EC with up to 10-fold increase in Annexin V binding Conclusion: HIV-specific CD8s from CP are endowed with an unexpectedly strong viral inhibition capacity when examined directly ex vivo. CD8s from EC and CP mediated similar HIV suppression directly ex vivo, while the superior antiviral activity of CD8s from EC after a 3d incubation was associated with better survival of HIV-specific CD8s. The capacity to survive and exert effector functions over extended periods, rather than the intrinsic antiviral capacity, best distinguishes CD8s from EC and CP.
Topic 11: T Cell Immunity P11.45 LB Loss and Regain of SIV Control Upon CD8+ Cell Depletion In Vivo In SIV-Controller Macaques Is Not Associated With Efficient SIV Specific CD8+ T-Cells C. Hamimi 1 , T. Bruel 2 , N. Dereuddre-Bosquet 2 , A. Cosma 2 , S. Shin 1 , A. Corneau 3 , P. Versmisse 1 , C. Torres 3 , B. Delache 3 , S. Even 3 , S. Guenounou 3 , B. Targat 3 , B. Malleret 3 , I. Karlsson 3 , F. Barré-Sinoussi 1 , R. Le-Grand 3 , G. Pancino 1 , A. Saez-Cirion 1 , B. Vaslin 3 1 Institut pasteur, Paris, France; 2 CEA, Division of Immuno- Virology, Institute of Emerging Diseases, Paris, France; 3 CEA, Division of Immuno-Virology, Institute of Emerging Diseases and I, Paris, France Background: Spontaneous long-term HIV/SIV control in HIVcontroller patients and SIV-controller macaques (SIC) is usually associated to protective MHC-class-I alleles and efficient CD8 T-cell responses. However, many HIV-controllers efficiently control HIV-infection despite of non-protective MHC background and weak CD8 T-cell responses, raising the question of real contribution of this response in maintaining viral control. We addressed this question by depleting in vivo CD8+ cells in SIC bearing or not protective MHC and weak CD8 T-cell responses. Methods: We studied five SIVmac -infected cynomolgous 251 macaques which maintained viremia
Page 2 and 3:
AIDS Vaccine 2012 PROGRAM AT A GLAN
Page 4 and 5:
AIDS Vaccine 2012 Partners www.alli
Page 6 and 7:
CONFERENCE ORGANIZERS Conference Or
Page 8 and 9:
CONFERENCE ORGANIZERS Conference Or
Page 10 and 11:
SCHOLARSHIP RECIPIENTS Awards and S
Page 12 and 13:
SCHOLARSHIP RECIPIENTS Awards and S
Page 14 and 15:
PROGRAM / MONDAY 2 Program Monday,
Page 16 and 17:
PROGRAM / MONDAY 4 Program 11:00 -
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
PROGRAM / TUESDAY 10 Program Tuesda
Page 24 and 25:
PROGRAM / TUESDAY 12 Program 11:45
Page 26 and 27:
PROGRAM / TUESDAY 14 Program 13:30
Page 28 and 29:
PROGRAM / TUESDAY 16 Program Poster
Page 30 and 31:
PROGRAM / TUESDAY 18 Program AIDS V
Page 32 and 33:
PROGRAM / WEDNESDAY 20 Program Wedn
Page 34 and 35:
22 AIDS Vaccine 2012
Page 36 and 37:
PLENARY SESSIONS 24 Plenary Session
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
SYMPOSIA SESSIONS 30 Symposia Sessi
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
ORAL ABSTRACT SESSIONS 54 Oral Abst
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
92 AIDS Vaccine 2012
Page 106 and 107:
POSTERS 94 AIDS Vaccine 2012
Page 108 and 109:
POSTERS 96 Posters Topic 1: Adjuvan
Page 110 and 111:
POSTERS 98 Posters Topic 1: Adjuvan
Page 112 and 113:
POSTERS Posters Topic 1: Adjuvants,
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
POSTERS Posters Topic 2: Animal Mod
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
POSTERS Posters Topic 3: B Cell Imm
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
POSTERS Posters Topic 4: Clinical V
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
POSTERS Posters Topic 5: HIV Transm
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
POSTERS Posters Topic 6: Immunogene
Page 192 and 193:
POSTERS Posters Topic 7: Innate Imm
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201: POSTERS Posters Topic 7: Innate Imm
Page 202 and 203: POSTERS Posters Topic 8: Mucosal Im
Page 212 and 213: POSTERS Posters Topic 9: Non-Vaccin
Page 222 and 223: POSTERS Posters Topic 10: Social/Et
Page 230 and 231: POSTERS Posters Topic 11: T Cell Im
Page 254 and 255: POSTERS Posters Topic 12: Vaccine C
Page 288 and 289: POSTERS Posters Topic 13: Pediatric
Page 290 and 291: AUTHOR INDEX Author Index Brander,
Page 292 and 293: AUTHOR INDEX Author Index Guan, Y .
Page 294 and 295: AUTHOR INDEX Author Index Lucas, J.
Page 296 and 297: AUTHOR INDEX Author Index Quinn, T
Page 298 and 299: AUTHOR INDEX Author Index Wendel-Ha
Page 300 and 301:
Notes 288
Page 302 and 303:
Notes 290
Page 305:
Poster Session 1 - Monday, 10 Septe
show all

Oral Abstract Session 01 - Global HIV Vaccine Enterprise

Create successful ePaper yourself

Delete template?

Save as template?